Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions.
Prospective Clinical Follow-up to Evaluate the Safety of Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions.
Inmunotek S.L.
80 participants
Jan 1, 2025
OBSERVATIONAL
Conditions
Summary
Observational clinical follow-up to evaluate the safety of immunotherapy for the treatment of hymenoptera venom allergy in real-life conditions. It includes the evaluation of controlled and spontaneous stings. This study will be conducted in Spain (multicentric), multicentric and data will be collected prospectively.
Eligibility
Inclusion Criteria4
- The study population consisted of allergic participants indicated for treatment with hymenoptera venom immunotherapy (Apis mellifera or Vespula spp.) according to standard clinical practice.
- Participants of both sexes aged 14 years or more.
- Participants who have not received immunotherapy with hymenoptera venom in the previous 5 years.
- Participants who have agreed to take part in the study and sign the informed consent form. In the case of minors, the patient's parent or guardian must also sign.
Exclusion Criteria4
- Pregnant or breastfeeding women.
- Having received immunotherapy with hymenoptera venom during the 5 years prior to the start of the study.
- Participants who do not agree to participate and/or do not sign the informed consent form.
- Participants who do not comply with medical indications or do not cooperate with immunotherapy treatment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Treatment with allergy vaccine against Vespula spp. (wasp) or Apis mellifera (bee), as per clinical indication.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06790368